Fda AI Medical Devices

FDA and AI Medical Devices

Artificial intelligence is moving rapidly from research labs into hospitals, clinics, and patient-facing apps, and the U.S. Food and Drug Administration is under pressure to keep pace. This hub tracks how regulators, manufacturers, and clinicians are navigating the approval, oversight, and real-world deployment of AI-powered medical technologies—from diagnostic imaging tools to generative AI systems that draft clinical notes or support treatment decisions.

The stakes are rising because AI in healthcare no longer fits neatly into traditional device categories. Software that learns and adapts over time, generative models that produce open-ended clinical text, and platforms built on patient-generated data all challenge a regulatory framework designed for static, hardware-based devices. As adoption accelerates across radiology, documentation, and patient engagement, questions about safety, transparency, liability, and data ownership are becoming harder to defer.

Readers here will find coverage of how the FDA is adapting its review processes and risk frameworks for adaptive and generative AI tools, how individual companies are testing the boundaries of existing rules, and how clinicians are weighing the benefits of AI assistance against risks of overreliance or error. The hub also covers efforts—by patients, startups, and decentralized data initiatives—to reshape who controls health data and how it fuels AI development.

Together, these threads capture a pivotal moment: the FDA and the broader healthcare ecosystem are working out, often in real time, what responsible AI oversight looks like when innovation is outpacing regulation. This page will continue to track that evolving balance as new tools, policies, and controversies emerge.